Use of triage strategies in the WHO signal-detection process

被引:28
作者
Lindquist, Marie [1 ]
机构
[1] UMC, WHO Collaborating Ctr Int Drug Monitoring, S-75320 Uppsala, Sweden
关键词
National Centre; System Organ Class; Signal Document; Triage Strategy; Uppsala Monitoring Centre;
D O I
10.2165/00002018-200730070-00014
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
An important role for the WHO Programme for International Drug Monitoring is to identify signals of international drug safety problems as early as possible. Since 1998, Bayesian Confidence Propagation Neural Network (BCPNN) data mining has been in routine use for screening of the WHO adverse reaction database, Vigibase. The identification of drug/adverse drug reaction combinations that have disproportionately high reporting relative to the background of all reports constitutes the first, quantitative step in the Uppsala Monitoring Centre (UMC) signal-detection process. In order to improve the signal-to-noise ratio and to focus on possible signals that are less likely to be detected by individual national pharmacovigilance centres, an expert group considered a number of possible subsidiary selection algorithms to be added as a second filtering step before potential signals were sent to the UMC expert panel for clinical review. As a result of these deliberations, three selection algorithms were implemented for routine use in 2001: 'serious reaction and new drug', 'rapid reporting increase' and 'special interest terms'. The effect of applying these algorithms has been critically evaluated on the basis of the ratio of associations selected to signals found and some modifications decided. Bearing in mind that any filtering strategy is likely to exclude some potential true signals from consideration, we think that triage strategies based on a combination of pragmatic thinking and experience are effective, provided that the results are reviewed at regular intervals and the algorithms adjusted on the basis of performance.
引用
收藏
页码:635 / 637
页数:3
相关论文
共 2 条
[1]   QUALITY CRITERIA FOR EARLY SIGNALS OF POSSIBLE ADVERSE DRUG-REACTIONS [J].
EDWARDS, IR ;
LINDQUIST, M ;
WIHOLM, BE ;
NAPKE, E .
LANCET, 1990, 336 (8708) :156-158
[2]  
Ståhl M, 2003, DRUG SAFETY, V26, P721